Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women’s Health Initiative study

References

• Shull JD, Spady TJ, Snyder MC, et al. Ovary-intact but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 1997;18:1595–601
   PubMed Web of Science ®Google Scholar
• Yue W, Wang J, Atkins KA, et al. Effect of a tissue selective estrogen complex on breast cancer: role of unique properties of conjugated equine estrogen. Int J Cancer 2018;143:1259–68
   PubMed Web of Science ®Google Scholar
• Santen RJ, Boyd NF, Chlebowski RT, et al. Breast Cancer Prevention Collaborative Group. Critical assessment of new risk factors for breast cancer: Considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007;14:169–87
   PubMed Web of Science ®Google Scholar
• Santen RJ. Endocrine-responsive cancer. In Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology, 11th ed. Philadelphia, PA: Saunders, 2008: 1763–83
   Google Scholar
• Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605–13
   PubMed Web of Science ®Google Scholar
• Feinleib M. Breast cancer and artificial menopause: A cohort study. J Natl Cancer Inst 1968;41:315–29
   PubMed Web of Science ®Google Scholar
• Nichols HB, Visvanathan K, Newcomb PA, et al. Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: Confounding by nonmalignant indications for surgery? Am J Epidemiol 2011;173:1111–20
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709–22
   PubMed Web of Science ®Google Scholar
• Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: reanalysis of Nine Prospective Studies. J Natl Cancer Inst 2002;94:606–16
   Google Scholar
• Tworoger SS, Rosner BA, Willett WC, Hankinson SE. The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: A nested case control study. Breast Cancer Res 2011;13:R99
   PubMed Web of Science ®Google Scholar
• Boyd NF, Melnichouk O, Martin LJ, et al. Mammographic density, response to hormones, and breast cancer risk. J Clin Oncol 2011;29:2985–92
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027–32
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer.. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC. The estrogen paradox. Nat Clin Pract Endocrinol Metab 2007;3:496–7
   PubMedGoogle Scholar
• Preston-Martin S, Pike MC, Ross RK, Henderson BE. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Perspect 1993;101:137–8
   PubMed Web of Science ®Google Scholar
• Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415–21
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108–13
   PubMed Web of Science ®Google Scholar
• Yue W, Wang JP, Li Y, et al. Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 2010;127:1748–57
   PubMed Web of Science ®Google Scholar
• Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006;1766:63–78
   PubMed Web of Science ®Google Scholar
• Gaikwad NW, Yang L, Pruthi S, et al. Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer 2009;3:1–8
   PubMedGoogle Scholar
• Gaikwad NW, Yang L, Muti P, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008;122:1949–57
   PubMed Web of Science ®Google Scholar
• Rogan EG, Badawi AF, Devanesan PD, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: Potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697–702
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270–82
   PubMed Web of Science ®Google Scholar
• Yager JD, Santen RJ. Mechanisms relating estrogen to breast cancer. Translation Endocrinol Metab 2012;3:75–93
   Google Scholar
• Savage KI, Matchett KB, Barros EM, et al. BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res 2014;74:2773–84
   PubMed Web of Science ®Google Scholar
• Korach KS. Estrogen receptor knock-out mice: Molecular and endocrine phenotypes. J Soc Gynecol Investig 2000;7:S16–S17
   PubMedGoogle Scholar
• Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 1999;59:1869–76
   PubMed Web of Science ®Google Scholar
• Devanesan P, Santen RJ, Bocchinfuso WP, et al. Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-1 mice: Implications for initiation of mammary tumors. Carcinogenesis 2001;22:1573–6
   PubMed Web of Science ®Google Scholar
• Yue W, Santen RJ, Wang JP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Molec Biol 2003;86:477–86
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 2012;21:1038–48
   PubMed Web of Science ®Google Scholar
• Bailey SL, Sigal BM, Plevritis SK. A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years. J Natl Cancer Inst 2010;102:1263–71
   PubMedGoogle Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Investigators WHI. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99:1335–9
   PubMed Web of Science ®Google Scholar
• Santen RJ, Song Y, Yue W, Wang JP, Heitjan DF. Effects of menopausal hormonal therapy on occult breast tumors. J Steroid Biochem Mol Biol 2013;137:150–6
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Heitjan DF. Occult breast tumor reservoir: biological properties and clinical significance. Horm Cancer 2013;4:195–207
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Endocrine Society. Postmenopausal hormone therapy: An endocrine society scientific statement. J Clin Endocrinol Metab 2010;95:S1–S66
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013;121:172–6
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65–73
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Cox DA, Song J, et al. Raloxifene and risk for stroke based on the Framingham stroke risk score. Am J Med 2009;122:754–61
   PubMed Web of Science ®Google Scholar
• Song RX, Zhang Z, Mor G, Santen RJ. Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 2005;10:667–78
   PubMed Web of Science ®Google Scholar
• Song RX, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003;8:55–60
   PubMed Web of Science ®Google Scholar
• Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001;93:1714–23
   PubMedGoogle Scholar
• Pathiraja TN, Nayak SR, Xi Y, et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 2014;6:229ra41
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167:1407–15
   PubMed Web of Science ®Google Scholar